Proton pump inhibitors

Medical treatment of gastroesophageal reflux in the neonatal intensive care unit: current practice

Posted on by Jeannine Sato

Journal of Perinatology, February 2025

Access article on PubMed.

Lockyear C, Stark A, Foote HP, Agyeman A, Bouleqcha M, Cohen N, Matusevich C, Pantsari A, Wang S, Rent S, Malcolm W, Tolia VN, Greenberg RG, Aleem S.

The objective of this study was to determine current prescribing practice of acid-suppressive therapy in preterm infants admitted to the neonatal intensive care unit (NICU). A cohort study of infants 22 to 27 weeks gestation were discharged from Pediatrix Medical Group NICUs between 2015 and 2020. The study showed that acid-suppressive therapies are used commonly in preterm infants and receipt is higher in infants with lower BWs. Use has significantly decreased over time and appears to be targeted, with many infants treated for one-week courses and without a diagnosis of GERD.

Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population

Posted on by Kayla Korzekwinski

CPT: Pharmacometrics & Systems Pharmacology • August 2024

Access article on PubMed.

Thompson EJ, Jeong A, Helfer VE, Shakhnovich V, Edginton A, Balevic SJ, James LP, Collier DN, Anand R, Gonzalez D., Best Pharmaceuticals for Children Act – Pediatric Trials Network

Pantoprazole is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease, a condition that disproportionately affects children with obesity. Appropriately dosing pantoprazole in children with obesity requires understanding the body size metric that best guides dosing, but pharmacokinetic (PK) trials using traditional techniques are limited by the need for larger sample sizes and frequent blood sampling. This study explored the effect of obesity on pantoprazole PK and evaluated label-suggested dosing in this population.

A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents

Posted on by Kayla Korzekwinski

Pediatric Drugs • October 2018

Access article on PubMed.

Shakhnovich V, Brian Smith P, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act–Pediatric Trials Network.

Pharmacokinetic data for proton pump inhibitors (PPIs), acid-suppression drugs commonly prescribed to children, are lacking for obese children who are at greatest risk for acid-related disease. In a recent multi-center investigation, we demonstrated decreased, total body weight adjusted, apparent clearance (CL/F) of the PPI pantoprazole for obese children compared with their non-obese peers.

Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures

Posted on by Kayla Korzekwinski

The Journal of Pediatrics • February 2018

Access article on PubMed.

Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL; Best Pharmaceuticals for Children Act – Pediatric Trials Network.

To assess appropriate pantoprazole dosing for obese children, we conducted a prospective pharmacokinetics (PK) investigation of pantoprazole in obese children, a patient population that is traditionally excluded from clinical trials. A total of 41 obese children (6-17 years of age), genotyped for CYP2C19 variants *2, *3, *4, and *17, received a single oral dose of pantoprazole, ~1.2 mg/kg lean body weight (LBW), with LBW calculated via a validated formula.

Use of Reflux Medications in Premature Infants After Hospital Discharge

Posted on by Kayla Korzekwinski

Pediatrics • December 2016

Access article on PubMed.

Smith PB

Medications are frequently used to treat gastroesophageal reflux (GER) in premature infants. However, diagnostic modalities for GER are poor and clinical diagnosis is highly variable. Despite the frequent use of GER medications in premature infants, short- or long-term benefits of GER medications in this population are undocumented. Studies in premature infants have failed to show a correlation between apnea, bradycardia, or respiratory symptoms typically thought to be due to GER. This study sought to fill these information gaps.